Advertisements



Sell Biogen Going Into Its Aducanumab BLA Filing

Sell Biogen Going Into Its Aducanumab BLA Filing.....»»

Category: topSource: seekingalphaNov 8th, 2019

Biogen Analysts Debate About-Face On Aducanumab: "Path To Market An Uphill Battle"

Biogen Inc (NASDAQ: BIIB) shares rallied strongly Tuesday after the biotech said it plans a regulatory filing for its Alzheimer's d.....»»

Category: blogSource: benzingaOct 23rd, 2019

Shares of Japan"s Eisai swamped with sell orders after ending Alzheimer trials

Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab......»»

Category: topSource: reutersMar 21st, 2019

Biogen Is A Buy Regardless Of Aducanumab

Biogen Is A Buy Regardless Of Aducanumab.....»»

Category: topSource: seekingalphaNov 6th, 2019

Biogen And Eisai"s Aducanumab: All That Glitters Is Not Gold

Biogen And Eisai"s Aducanumab: All That Glitters Is Not Gold.....»»

Category: topSource: seekingalphaNov 4th, 2019

Biogen Aducanumab Reversal Is Stunning, But Don"t Expect A Repeat For Other Alzheimer"s Drugs

Biogen Aducanumab Reversal Is Stunning, But Don"t Expect A Repeat For Other Alzheimer"s Drugs.....»»

Category: topSource: seekingalphaOct 24th, 2019

Morgan Stanley withholds aducanumab judgement for now, stays Underweight Biogen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 23rd, 2019

Biogen, Eisai revive plans for Alzheimer"s drug, surprising market

Biogen Inc revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients......»»

Category: topSource: reutersOct 23rd, 2019

Cantor "inclined to believe" Biogen has "strong evidence" to advance aducanumab

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Biogen Plans Filing For Failed Alzheimer"s Drug After New Analysis

Biogen Inc (NASDAQ: BIIB) share.....»»

Category: earningsSource: benzingaOct 22nd, 2019

Biogen Plans Filing For Failed Alzheimer"s Drug After New Analysis

Biogen Inc (NASDAQ: BIIB) shares, which suffered a severe setback in early 2019 after the company's Alzheimer's program flopped, were seeing a resurgence Tuesday.  read more.....»»

Category: blogSource: benzingaOct 22nd, 2019

Biogen says "just started" to contact European regulators about aducanumab

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Biogen says FDA saw filing as "reasonable"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Questions remain about Biogen"s aducanumab despite plan to file, says Mizuho

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

RBC says Biogen aducanumab data may be more mixed than initially perceived

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Biogen CEO says aducanumab result gives hope for BAN2401

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Biogen resurrects Alzheimer"s drug; shares jump 35%

Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies......»»

Category: topSource: moneycentralOct 22nd, 2019

Biogen to offer access to aducanumab to patients enrolled in Phase 3 studies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Biogen: Analysis of larger dataset showed aducanumab reduced clinical decline

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Biogen plans aducanumab BLA in early 2020 based on FDA talks

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Biogen plans aducanumab BLA in early 2020 based on FDA talks

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019